Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 28 results.
User Information
Export Records
  1. 1.   Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins
  2. Tewary,Poonam; Brooks, Alan D.; Xu, Ya-Ming; Wijeratne, E. M. Kithsiri; Babyak, Ashley L.; Back, Timothy C.; Chari,Raj; Evans,Christine; Henrich,Curtis; Meyer,Thomas; Edmondson,Elijah; de Aquino, Maria T. Prudente; Kanagasabai, Thanigaivelan; Shanker, Anil; Gunatilaka, A. A. Leslie; Sayers, Thomas J.
  3. Cancer Research. 2021, Jun 15; 81(12): 3374-3386.
  1. 2.   SMAC Mimetic/IAP Inhibitor Birinapant Enhances Radiosensitivity of Glioblastoma Multiforme
  2. Cerna, David; Lim, Bora; Adelabu, Yusuf; Yoo, Stephen; Carter, Donna; Fahim, Ahmed; Mitsuuchi, Yasuhiro; Teicher, Beverly A.; Bernhard, Eric; Coleman, C. Norman; Takebe, Naoko; Ahmed, Mansoor M.
  3. Radiation Research. 2021, Jun; 195(6): 549-560.
  1. 3.   Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model
  2. Yamamoto, Jun; Miyake, Kentaro; Han, Qinghong; Tan, Yuying; Inubushi, Sachiko; Sugisawa, Norihiko; Higuchi, Takashi; Tashiro, Yoshihiko; Nishino, Hiroto; Homma, Yuki; Matsuyama, Ryusei; Chawla, Sant P; Bouvet, Michael; Singh,Shree Ram; Endo, Itaru; Hoffman, Robert M
  3. Cancer letters. 2020, NOV 1; 492: 174-184.
  1. 4.   Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis
  2. Henrich, C. J.; Thomas, C. L.; Brooks, A. D.; Booth, N. L.; Lowery, E. M.; Pompei, R. J.; McMahon, J. B.; Sayers, T. J.
  3. Apoptosis. 2012, Jan; 17(1): 79-89.
  1. 5.   Protein delivery using engineered virus-like particles
  2. Kaczmarczyk, S. J.; Sitaraman, K.; Young, H. A.; Hughes, S. H.; Chatterjee, D. K.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2011, Oct; 108(41): 16998-17003.
  1. 6.   Targeting the extrinsic apoptosis signaling pathway for cancer therapy
  2. Sayers, T. J.
  3. Cancer Immunology Immunotherapy. 2011, Aug; 60(8): 1173-1180.
  1. 7.   Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of Response
  2. Kang, Z. G.; Chen, J. J.; Yu, Y. K.; Li, B.; Sun, S. Y.; Zhang, B. L.; Cao, L.
  3. Clinical Cancer Research. 2011, May; 17(10): 3181-3192.
  1. 8.   HIV-1 impairs in vitro priming of naive T cells and gives rise to contact-dependent suppressor T cells
  2. Che, K. F.; Sabado, R. L.; Shankar, E. M.; Tjomsl, V.; Messmer, D.; Bhardwaj, N.; Lifson, J. D.; Larsson, M.
  3. European Journal of Immunology. 2010, Aug; 40(8): 2248-2258.
  1. 9.   Bortezomib Sensitizes Human Esophageal Squamous Cell Carcinoma Cells to TRAIL-Mediated Apoptosis via Activation of Both Extrinsic and Intrinsic Apoptosis Pathways
  2. Seki, N.; Toh, U.; Sayers, T. J.; Fujii, T.; Miyagi, M.; Akagi, Y.; Kusukawa, J.; Kage, M.; Shirouzu, K.; Yamana, H.
  3. Molecular Cancer Therapeutics. 2010, Jun; 9(6): 1842-1851.
  1. 10.   Bortezomib Sensitizes Human Renal Cell Carcinomas to TRAIL Apoptosis through Increased Activation of Caspase-8 in the Death-Inducing Signaling Complex
  2. Brooks, A. D.; Jacobsen, K. M.; Li, W. Q.; Shanker, A.; Sayers, T. J.
  3. Molecular Cancer Research. 2010, May; 8(5): 729-738.
  1. 11.   Breast cancer bone metastases Combination therapy targeting cancer cells and the tumor microenvironment
  2. de Kluyver, R. L.; Sayers, T. J.
  3. Cancer Biology & Therapy. 2010, Apr; 9(7): 551-553.
  1. 12.   Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody
  2. Feng, Y.; Xiao, X. D.; Zhu, Z. Y.; Dimitrov, D. S.
  3. Mabs. 2010, Sep-Oct; 2(5): 565-570.
  1. 13.   Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody
  2. Shanker, A.; Brooks, A. D.; Tristan, C. A.; Wine, J. W.; Elliott, P. J.; Yagita, H.; Takeda, K.; Smyth, M. J.; Murphy, W. J.; Sayers, T. J.
  3. Journal of the National Cancer Institute. 2008 100(9): 649-662.
  1. 14.   Sensitizing tumor cells to immune-mediated cytotoxicity
  2. Shanker, A.; Sayers, T.
  3. Immune-Mediated Diseases: From Theory to Therapy. 2007; 601 : 163-171.
  1. 15.   Therapeutic modulation of Akt activity and antitumor efficacy of interleukin-12 against orthotopic murine neuroblastoma
  2. Khan, T.; Hixon, J. A.; Stauffer, J. K.; Lincoln, E.; Back, T. C.; Brenner, J.; Lockett, S.; Nagashima, K.; Powell, D.; Wigginton, J. M.
  3. Journal of the National Cancer Institute. 2006, FEB 1; 98(3): 190-202.
  1. 16.   TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer
  2. Cretney, E.; Shanker, A.; Yagita, H.; Smyth, M. J.; Sayers, T. J.
  3. Immunology and Cell Biology. 2006, FEB; 84(1): 87-98.
  1. 17.   Intracellular signals and events activated by cytokines of the tumor necrosis factor superfamily: From simple paradigms to complex mechanisms
  2. Grivennikov, S. I.; Kuprash, D. V.; Liu, Z. G.; Nedospasov, S. A.
  3. International Review of Cytology - a Survey of Cell Biology, Vol 252. 2006; 252 : 129-+.
  1. 18.   Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy
  2. Sayers, T. J.; Murphy, W. J.
  3. Cancer Immunology Immunotherapy. 2006, JAN; 55(1): 76-84.
  1. 19.   Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis
  2. Brooks, A. D.; Sayers, T. J.
  3. Cancer Immunology Immunotherapy. 2005, MAY; 54(5): 499-505.
  1. 20.   TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells
  2. Herbeuval, J. P.; Boasso, A.; Grivel, J. C.; Hardy, A. W.; Anderson, S. A.; Dolan, M. J.; Chougnet, C.; Lifson, J. D.; Shearer, G. M.
  3. Blood. 2005 105(6): 2458-2464.
  1. 21.   The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis
  2. Brooks, A. D.; Ramirez, T.; Toh, U.; Onksen, J.; Elliott, P. J.; Murphy, W. J.; Sayers, T. J.
  3. Tumor Progression and Therapeutic Resistance. 2005; 1059 : 160-167.
  1. 22.   Components of the cell death machine and drug sensitivity of the National Cancer Institute cell line panel
  2. Svingen, P. A.; Loegering, D.; Rodriquez, J.; Meng, X. W.; Mesner, P. W.; Holbeck, S.; Monks, A.; Krajewski, S.; Scudiero, D. A.; Sausville, E. A.; Reed, J. C.; Lazebnik, Y. A.; Kaufmann, S. H.
  3. Clinical Cancer Research. 2004, OCT 15; 10(20): 6807-6820.
  1. 23.   Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy
  2. Takeda, K.; Yamaguchi, N.; Akiba, H.; Kojima, Y.; Hayakawa, Y.; Tanner, J. E.; Sayers, T. J.; Seki, N.; Okumura, K.; Yagita, H.; Smyth, M. J.
  3. Journal of Experimental Medicine. 2004 199(4): 437-448.
  1. 24.   Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils
  2. Kamohara, H.; Matsuyama, W.; Shimozato, O.; Abe, K.; Galligan, C.; Hashimoto, S. I.; Matsushima, K.; Yoshimura, T.
  3. Immunology. 2004 111(2): 186-194.
  1. 25.   The proteasorne inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP
  2. Sayers, T. J.; Brooks, A. D.; Koh, C. Y.; Ma, W. H.; Seki, N.; Raziuddin, A.; Blazar, B. R.; Zhang, X.; Elliott, P. J.; Murphy, W. J.
  3. Blood. 2003 102(1): 303-310.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel